NICE has recommended regular NHS funding for Opdivo in advanced melanoma, including in combination with BMS' other immunotherapy, Yervoy. It has also backed Keytruda in advanced skin cancer.
Zacks Investment Research on MSN5d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Due to federal research cuts, Navy veteran Kyle Lewis says he won't be able to receive the cancer treatment that saved his ...
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
2d
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback